Engineered mRNA 5'UTR Design for Consistent Protein Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Inconsistent protein expression levels following in vitro transcribed mRNA (IVT mRNA) delivery in vivo necessitate the development of highly efficient 5' untranslated regions (5'UTRs) to enhance mRNA expression efficiency.

Innovation Solution

Engineered mRNA comprising specific 5'UTR sequences, 3'UTR sequences, and an open reading frame (ORF), optimized for protein production, are encapsulated in vectors and delivered via lipid nanoparticles, ensuring synergistic enhancement of protein expression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional IVT mRNA is used, then production flexibility and cost-effectiveness are improved, but protein expression levels in vivo are inconsistent and insufficient

Engineering Contradiction:
Improveprotein expression levelVSAvoidexpression consistency
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent applies parameter changes by optimizing the 5'UTR sequence parameters including GC content (40-60%), length (30-70 nucleotides), and specific sequence composition to enhance ribosome binding efficiency. This systematic parameter optimization resolves the contradiction by making protein expression levels both higher and more consistent across different mRNA products while maintaining the flexibility of the IVT platform

Inventive Principle:
Principle #35Parameter changes

2Productivity

If the 5'UTR sequence is optimized for high translation efficiency, then protein production increases, but mRNA structure stability may be compromised

Engineering Contradiction:
Improvetranslation efficiencyVSAvoidmRNA structural stability
Core Design Contradiction:
ProductivityVSStability of the object's composition

Solution Approach 1:

The patent applies local quality by creating specific functional zones within the 5'UTR: a stable structural core region (with optimized GC content and secondary structure elements) and a ribosome access region (with optimized Kozak sequence and spacing). This local differentiation allows the mRNA to simultaneously achieve structural stability for protection and localized high-efficiency translation initiation

Inventive Principle:
Principle #3Local quality

Data Source

PatentEP4711466A1Engineered mRNA and use thereof
Publication Date: 2026.03.18 XIANWEI (HAINAN) BIOTECHNOLOGY CO LTD
  • EP4711466A1 patent drawingFigure 1~3
  • EP4711466A1 patent drawingFigure 4~5
  • EP4711466A1 patent drawingFigure 6~7

AI summary

Provided are an engineered mRNA and a method for improving protein expression using same. Also provided is the use of such engineered mRNA in gene therapy and/or genetic vaccination.